{"product_id":"progyny-pestle-analysis","title":"Progyny PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock how political, economic, social, technological, legal, and environmental forces are reshaping Progyny’s prospects with our concise PESTLE Analysis—ideal for investors and strategists seeking actionable external insights; purchase the full report to access detailed risk assessments, growth opportunities, and ready-to-use slides and spreadsheets for immediate strategic impact.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFederal Reproductive Health Legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe late-2025 federal debate on reproductive health could yield mandates standardizing fertility coverage or impose restrictions; Progyny must track proposals—Congressional bills in 2025 targeted an estimated 20–30 million insured adults—since federal rules would materially affect addressable market and reimbursement models.\u003c\/p\u003e\n\u003cp\u003eOpposing outcomes could shift employer demand: a federal coverage mandate may expand payroll-funded fertility benefits, potentially increasing Progyny’s TAM by an estimated $1.2–2.0 billion annually; restrictions would raise compliance costs and operational complexity.\u003c\/p\u003e\n\u003cp\u003ePolitical stability around the Affordable Care Act remains a key variable—ACA enrollment topped 18.9 million in 2024—which continues to shape employer-sponsored benefit design, influencing Progyny’s product positioning for diverse workforces and cost-sharing strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState-Level Fertility Mandates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA growing number of states—29 as of 2025—have enacted mandates requiring private insurers to cover fertility treatments, creating a complex patchwork of compliance that Progyny navigates across markets.\u003c\/p\u003e\n\u003cp\u003eProgyny leverages these mandates to persuade self-insured employers to adopt standardized, enhanced benefits that often exceed state minimums, supporting retention and pricing power; clients using Progyny report average per-member-per-month savings of up to 20% versus traditional IVF approaches (2024 data).\u003c\/p\u003e\n\u003cp\u003eRapid political shifts in state legislatures can quickly raise or relax baseline requirements, altering addressable market size regionally and impacting Progyny’s penetration and topline growth forecasts in those states.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTax Incentives for Employer-Sponsored Benefits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical decisions on tax-advantaged employer benefits directly affect Progyny’s affordability for clients; employer-sponsored plans cover about 49% of US healthcare spending, and changes capping tax exclusions (current estimate ~$36B annual tax preference for employer health) could pressure high-value niche benefits like fertility care. Progyny actively lobbies; in 2024 it reported advocacy and policy engagement expenses aligned to preserving fertility-related tax exclusions to protect client cost structures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Health Policy and International Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs Progyny targets international expansion, diplomatic relations and country-specific healthcare regulations critically affect market entry; for example, EU GDPR fines reached 1.8 billion euros in 2024, heightening cross-border data transfer risks for fertility patient records.\u003c\/p\u003e\n\u003cp\u003eCountries vary widely: Israel and Japan offer supportive frameworks and public subsidies for ART, while several Latin American nations maintain restrictive laws, impacting addressable market size and reimbursement models.\u003c\/p\u003e\n\u003cp\u003eNavigating these jurisdictions demands local licensing, compliance with telehealth and tissue\/embryo transport rules, and partnerships to mitigate political and regulatory risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGDPR fines 2024: €1.8B — impacts data transfer compliance\u003c\/li\u003e\n\u003cli\u003eSupportive markets (e.g., Israel, Japan): public subsidies expand TAM\u003c\/li\u003e\n\u003cli\u003eRestrictive regimes: limit service offerings and revenue streams\u003c\/li\u003e\n\u003cli\u003eMitigation: local partners, licensing, data localization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Sector Benefit Adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical momentum is growing to extend fertility benefits to government and military employees, with several states passing mandates and the 2024 federal employee benefits review recommending expanded reproductive care; this boosts market opportunity for Progyny, which reported $476.4 million revenue in 2024, a selling point for public contracts.\u003c\/p\u003e\n\u003cp\u003eProgyny’s public-sector sales hinge on election cycles and annual federal\/state budget approvals, making contract timing and renewals politically sensitive; successful inclusion in public health plans—demonstrated by pilot programs showing up to 30% per-member cost savings—strengthens its negotiation position.\u003c\/p\u003e\n\u003cp\u003eIntegration into public plans serves as high-profile validation of Progyny’s clinical and cost-saving model, aiding broader adoption across jurisdictions where government procurement can unlock large, stable enrollment pools.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrowing political support and state mandates increase addressable public-sector market\u003c\/li\u003e\n\u003cli\u003eRevenue scale ($476.4M in 2024) aids credibility in bids\u003c\/li\u003e\n\u003cli\u003eDependence on election cycles and budgets creates timing risk\u003c\/li\u003e\n\u003cli\u003ePilot data showing ~30% cost savings bolsters procurement wins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProgyny: Mandates, GDPR fines, and tax shifts could boost TAM $1.2–2B vs $476M revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFederal\/state fertility mandates, ACA stability, tax policy, and international regs (GDPR €1.8B fines) materially reshuffle Progyny’s TAM, compliance costs, and public-sector sales; 2024 revenue $476.4M, potential TAM shift $1.2–2.0B with federal mandate, 29 states with mandates (2025), employer health covers ~49% of US spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$476.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eState mandates (2025)\u003c\/td\u003e\n\u003ctd\u003e29\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGDPR fines 2024\u003c\/td\u003e\n\u003ctd\u003e€1.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated TAM lift (federal)\u003c\/td\u003e\n\u003ctd\u003e$1.2–2.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Progyny across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and forward-looking insights to identify threats and opportunities for executives, investors, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCompact PESTLE summary tailored to Progyny that highlights regulatory, technological, and demographic risks and opportunities for quick reference in meetings or presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Inflation and Cost Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent medical inflation—healthcare CPI rose 5.1% in 2024 and remained elevated into 2025—has strained employer benefits budgets, making Progyny’s cost-containment attractive as employers seek predictable spend.\u003c\/p\u003e\n\u003cp\u003eProgyny reduces high-risk multiple births and boosts live-births-per-cycle, helping avoid NICU costs that average over $76,000 per infant and can exceed $1 million for extreme prematurity.\u003c\/p\u003e\n\u003cp\u003eEconomic volatility and wage inflation drive demand for specialized benefit managers; Progyny’s bundled-pricing and outcomes-based contracts offer employers predictable pricing amid fluctuating unit costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor Market Competitiveness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompetition for high-skilled talent drives demand for Progyny’s fertility solutions; 72% of employers offered enhanced family benefits in 2024 to attract\/retain specialists, and firms report a 15–20% retention uplift when providing fertility benefits like IVF and egg-freezing, positioning these costs as strategic investments in human capital rather than overhead.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Out-of-Pocket Spending Power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic conditions shaping disposable income directly affect employee uptake of elective fertility benefits; US real median household income rose 0.4% in 2023 after inflation but remained 2.1% below 2019 levels, suggesting sensitivity in utilization.\u003c\/p\u003e\n\u003cp\u003eProgyny lowers out-of-pocket costs, yet a recession could postpone family-building—during the 2020–2021 downturn elective fertility cycles fell by ~10–15% industrywide.\u003c\/p\u003e\n\u003cp\u003eMonitoring consumer confidence (Conference Board index fell to 99.3 in Jan 2024) and wage growth (average hourly earnings up 3.6% YoY in 2024) is essential for forecasting utilization and revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy Benefit Management Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe rising cost of specialty drugs, including fertility biologics, drove US specialty drug spend up ~13% in 2024 to $420B, pressuring health plans in 2025; fertility drug cycles can cost $10k–$25k with add-on biologics. Progyny Rx targets medication optimization and waste reduction, claiming per-member savings via adherence and dispensing controls that improve client ROI.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialty drug spend +13% in 2024 to $420B\u003c\/li\u003e\n\u003cli\u003eFertility cycles often $10k–$25k; biologics add significant cost\u003c\/li\u003e\n\u003cli\u003eProgyny Rx reduces waste and improves adherence, boosting client ROI\u003c\/li\u003e\n\u003cli\u003eNegotiation\/management of high-cost biologics critical to margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rates and Capital Allocation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs of late 2025, the US federal funds rate near 5.25–5.50% raised Progyny’s weighted average borrowing costs, constraining leverage for acquisitions and pushing management toward ROI-focused tech investments and margin initiatives.\u003c\/p\u003e\n\u003cp\u003eHigher yields favor conserving cash; Progyny reported about $200–300M in liquidity (2024–2025 range), prompting investors to watch capex versus R\u0026amp;D spend to sustain competitive innovation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrevailing rates ~5.25–5.50%\u003c\/li\u003e\n\u003cli\u003eLiquidity roughly $200–300M (2024–2025)\u003c\/li\u003e\n\u003cli\u003eStrategy tilt: organic growth, margin improvement, selective tech spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising costs boost Progyny's outcomes-based value as liquidity curbs M\u0026amp;A\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic headwinds—healthcare CPI +5.1% (2024), specialty drug spend +13% to $420B (2024), federal funds ~5.25–5.50% (late 2025)—increase employer costs and elevate Progyny’s value proposition via predictable, outcomes-based pricing; liquidity ~$200–300M (2024–25) limits M\u0026amp;A, favoring ROI-focused tech and Rx waste reduction to protect margins and utilization.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare CPI (2024)\u003c\/td\u003e\n\u003ctd\u003e+5.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty drug spend (2024)\u003c\/td\u003e\n\u003ctd\u003e$420B (+13%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds (late 2025)\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiquidity (2024–25)\u003c\/td\u003e\n\u003ctd\u003e$200–300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eProgyny PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Progyny PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic planning and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751927492985,"sku":"progyny-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/progyny-pestle-analysis.png?v=1772236298","url":"https:\/\/growthsharematrix.com\/products\/progyny-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}